logo

For the Inventor, By the Inventor

Princeton, NJ, United States of America

Gary R Matsueda

This inventor holds 18 USPTO granted patents, primarily in Fibrinolysis Research. Top assignees: The General Hospital Corporation, Bristol-Myers Squibb Compnay, Harvard College. Active years: 1982-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gary R Matsueda. Retrieved from https://idiyas.com/inventor/gary-r-matsueda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 88.9

Average Co-Inventor Count = 2.8

ph-index = 6

Forward Citations = 176(Granted Patents)


Location History:

  • Winchester, MA (US) (1982 - 1994)
  • Princeton, NJ (US) (1994 - 2007)

Company Filing History:

goldMedal15 out of 3,076 
 
The General Hospital Corporation
 patents
silverMedal5 out of 3,745 
 
Bristol-Myers Squibb Compnay
 patents
bronzeMedal1 out of 3,078 
 
Harvard College
 patents
where one patent can have more than one assignee

Years Active: 1982-2007

Loading Chart...
Areas of Expertise:
Fibrin-specific Antibodies
Polypeptides
Clot Lysis
Thrombolytic Agents
Nucleic Acid Molecules
Activation-dependent Proteins
Factor XIII Inhibition
Synthetic Peptides
Monoclonal Antibodies
Thrombin-activatable Plasminogen
Antibody Fragments
18 patents (USPTO):Explore Patents
1. 7189829 - Baboon TAFI polypeptides (2007-03-13),
2. 7091331 - Nucleic acid molecules and polypeptides encoding baboon TAFI (2006-08-15),
3. 6576431 - Antibodies that bind to &agr;2-antiplasmin crosslinked to fibrin which do not inhibit plasma &agr;2-antiplasmin (2003-06-10),
4. 6280730 - Antibodies that bind to &agr;2-antiplasmin crosslinked to fibrin which do not inhibit plasma &agr;2-antiplasmin (2001-08-28),
5. 6114506 - Composition and method for enhancing fibrinolysis (2000-09-05),
6. 5831031 - Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibrin which (1998-11-03),
7. 5773228 - Activation-dependent protein expressed on the surface of activated (1998-06-30),
8. 5620688 - Methods of inhibiting the activation of Factor XIII (1997-04-15),
9. 5582862 - Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibrin which (1996-12-10),
10. 5571708 - Thrombin-activatable plasminogen activator (1996-11-05),
11. 5446132 - Thrombin-activated platelet protein-2 (TAPP-2) (1995-08-29),
12. 5372812 - Composition and method for acceleration of clot lysis (1994-12-13),
13. 5357042 - Synthetic peptides capable of eliciting fibrin-specific monoclonal (1994-10-18),
14. 5256413 - Method and use for site-specific activation of substances (1993-10-26),
15. 5116613 - Antibody-thrombolytic agent product and method of use (1992-05-26),

Title: Gary R Matsueda: Innovator in Blood Clotting Research

Introduction

Gary R Matsueda is a prominent inventor based in Princeton, NJ (US). He has made significant contributions to the field of blood clotting research, holding a total of 18 patents. His work focuses on the development of novel therapeutic agents that can regulate blood clotting, which is crucial for treating various blood disorders.

Latest Patents

One of Matsueda's latest patents involves the isolation and identification of novel baboon thrombin-activatable fibrinolysis inhibitors, known as TAFI. This invention relates to the discovery of baboon nucleic acid molecules and the proteins and polypeptides they encode. The novel baboon TAFI proteins and polypeptides inhibit the breakdown of blood clots, making them potentially useful for treating conditions such as hemophilia and von Willebrand's disease. Additionally, these sequences can be utilized in screening methods to identify compounds that modulate the expression of baboon TAFI nucleic acids and their activity. Such compounds may serve as agonists or antagonists in the treatment of various thrombotic diseases, including deep venous thrombosis and coronary artery disease.

Career Highlights

Throughout his career, Gary R Matsueda has worked with notable organizations, including The General Hospital Corporation and Bristol-Myers Squibb Company. His innovative research has led to advancements in understanding blood clotting mechanisms and developing therapeutic solutions.

Collaborations

Matsueda has collaborated with esteemed colleagues such as Edgar Haber and Guy L Reed, contributing to the advancement of research in his field.

Conclusion

Gary R Matsueda's contributions to blood clotting research and his innovative patents highlight his role as a key inventor in the medical field. His work continues to pave the way for new treatments that can improve the lives of individuals with blood disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…